A Prospective Multicenter Randomized Controlled Study on Interleukin-6 Removal and Induction by a new Hemodialyzer With Improved Biocompatibility in Hemodialysis Patients: A Pilot Study

Therapeutic Apheresis and Dialysis

Volumn 20, Issue 6, 2016, Pages 569-578

  Kakuta, Takatoshi ^a,b   Komaba, Hirotaka ^b   Takagi, Nobuyoshi ^c   Takahashi, Yuichiro ^d   Suzuki, Hajime ^b   Hyodo, Toru ^e   Nagaoka, Mikako ^f   Tanaka, Reika ^g   Iwao, Soichiro ^h   Ishida, Mari ^a   Kobayashi, Hiroyuki ^b   Saito, Akira ^b   Fukagawa, Masafumi ^b  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Kannai Suzuki Clinic   (Japan)

^d Jinken Clinic   (Japan)

^e Department of Urology and Blood Purification Kuratakai Eijin Clinic   (Japan)

^f Hon Atsugi Medical Clinic   (Japan)

^g Bohsei Ohone Clinic   (Japan)

^h Chigasaki Central Hospital   (Japan)

Author keywords

Biocompatibility; Erythropoiesis stimulating agent; Hemodialysis; Inflammatory cytokine

Indexed keywords

BETA 2 MICROGLOBULIN; HEMOGLOBIN; INTERLEUKIN 6; POLYMER; POLYSULFONE P 1700; SULFONE;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON METABOLISM; MALE; MULTICENTER STUDY; NUTRITIONAL STATUS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; CLINICAL TRIAL; DIALYZER; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; KIDNEYS, ARTIFICIAL; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMERS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SULFONES; TREATMENT OUTCOME;

EID: 84982973090     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12454     Document Type: Article

References (27)

1. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002;15:329–37.
2. Pecoits-Filho R, Bárány P, Lindholm B et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684–8.
3. Rao M, Guo D, Perianayagam MC et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005;45:324–33.
4. Bárány P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemdialysis patients. Am J Kidney Dis 1997;29:565–8.
5. Bradbury BD, Critchlow CW, Weir MR et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 2009;24:919–25.
6. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000;15:1207–11.
7. Rattanasompattikul M, Molnar MZ, Zaritsky JJ et al. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant 2013;28:1936–45.
8. Girndt M, Stenvinkel P, Ulrich C et al. Influence of cytokine gene polymorphisms on erythropoietin dose requirements in chronic haemodialysis patients. Nephrol Dial Transplant 2007;22:3586–92.
9. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predicts mortality in hemodialysis patients. Am J Kidney Dis 2004;44:866–76.
10. Rossert J, Gassmann-Mayer C, Frei D et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007;22:794–800.
11. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 2003;18:1042–5.
12. Goicoechea M, Martin J, De Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998;54:1337–43.
13. Memoli B, Postiglione L, Cianciaruso B et al. Role of different dialysis membranes in the release of interleutin-6-soluble receptor in uremic patients. Kidney Int 2000;58:417–24.
14. Caglar K, Peng Y, Pupim LB et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002;62:1408–16.
15. Hatakeyama T, Tanaka M, Hatakeyama H. Studies on bound water restrained by poly(2-methacryloyloxyethyl phosphorylcholine): Comparison with polysaccharide-water systems. Acta Biomater 2010;6:2077–82.
16. Tsuruta T. On the role of water molecules in the interface between biological systems and polymers. J Biomater Sci Polym Ed 2010;21:1831–48.
17. Tanaka M, Hayashi T, Morita S. The roles of water molecules at the biointerface of medical polymers. Polymer J 2013;45:701–10.
18. Yamaka T, Ichikawa K, Saito M et al. Biocompatibility of the new anticoagulant dialyzer TORAYLIGHT® NV. Science Postprint 2014;1:e00020.
19. Hidaka S, Kobayashi S, Maesato K et al. Hydrophilic polymer-coated polysulfone membrane improves endothelial function of hemodialysis patients: a pilot study. J Clin Nephrol Res 2015;2:1020.
20. Di Campli C, Zocco MA, Gaspari R et al. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 2005;37:2551–3.
21. Peng Y, Yuan Z, Li H. Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns 2005;31:623–8.
22. Kawanishi H, Akiba T, Masakane I et al. Standard on microbiological management of fluids for hemodialysis and related therapies by the Japanese Society for Dialysis Therapy 2008. Ther Apher Dial 2009;13:161–6.
23. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63–72.
24. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G et al. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004;19:1507–519.
25. Kobayashi I, Ishimura E, Kato Y et al. Geriatric Nutritional Risk Index, a simplified nutritional screening index, is a significant predictor of mortality in chronic dialysis patients. Nephrol Dial Transplant 2010;25:3361–5.
26. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783–8.
27. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461–3.